2024
The effect of plerixafor on autologous stem cell mobilization, cell viability, and apheresis challenges
Puzo C, Li P, Tormey C, Siddon A. The effect of plerixafor on autologous stem cell mobilization, cell viability, and apheresis challenges. Lab Medicine 2024, lmae080. PMID: 39303673, DOI: 10.1093/labmed/lmae080.Peer-Reviewed Original ResearchAutologous stem cell transplantationHematopoietic stem cellsMultiple myelomaG-CSFMobilization failureDiffuse large B-cell lymphomaAutologous stem cell mobilizationLarge B-cell lymphomaGranulocyte colony-stimulating factorAutologous stem cell transplant patientsEfficacy of plerixaforStem cell mobilizationB-cell lymphomaStem cell transplantationEffects of plerixaforRetrospective chart reviewColony-stimulating factorYale-New Haven HospitalCell viabilityMultiple risk factorsHodgkin lymphomaNon-HodgkinMobilization regimenCell transplantationPlerixaforMixed-field ABO front typing as an early sign of disease recurrence in ABO-matched stem cell transplantation
Yurtsever N, Lee E, Pinatti L, Shah B, Tormey C, Siddon A. Mixed-field ABO front typing as an early sign of disease recurrence in ABO-matched stem cell transplantation. Immunohematology 2024, 40: 89-92. PMID: 39373301, DOI: 10.2478/immunohematology-2024-013.Peer-Reviewed Original ResearchConceptsStem cell transplantationCell transplantationDisease recurrenceMyeloid neoplasmsChimerism testingAllogeneic stem cell transplantationSigns of disease recurrenceIndicator of disease recurrenceDonor-recipient pairsABO antigen expressionGraft statusAntigen expressionFemale patientsPost-transplantationAllograft statusTransplantationABO typeRecurrenceClinical settingEarly signsNeoplasmsChimerismEarly indicatorABOEngraftment
2023
Myelodysplastic Syndromes
Siddon A. Myelodysplastic Syndromes. Clinics In Laboratory Medicine 2023, 43: i. DOI: 10.1016/s0272-2712(23)00095-1.Peer-Reviewed Original ResearchAdvances in Myelodysplastic Syndromes
Siddon A. Advances in Myelodysplastic Syndromes. Clinics In Laboratory Medicine 2023, 43: xiii-xiv. PMID: 37865512, DOI: 10.1016/j.cll.2023.08.015.Peer-Reviewed Original ResearchDiagnosis and Classification of Myelodysplastic Syndromes with Mutated TP53
Siddon A, Weinberg O. Diagnosis and Classification of Myelodysplastic Syndromes with Mutated TP53. Clinics In Laboratory Medicine 2023, 43: 607-614. PMID: 37865506, DOI: 10.1016/j.cll.2023.07.004.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMyelodysplastic syndromeTP53 mutationsPrognosis of MDSCases of MDSPrognostic scoring systemNext-generation sequencingParticular next-generation sequencingAggressive diseasePoor outcomeTherapeutic managementTP53 disruptionMyeloid leukemiaMyeloid neoplasmsTherapeutic advancementsCytogenetic abnormalitiesMyeloid neoplasiaScoring systemDisease classificationMyeloid diseasesGene mutationsSyndromeDiseaseDiagnosisTP53Current clinical practices and challenges in molecular testing: a GOAL Consortium Hematopathology Working Group report
Lee T, Aisner D, David M, Eno C, Gagan J, Gocke C, Guseva N, Haley L, Jajosky A, Jones D, Mansukhani M, Mroz P, Murray S, Newsom K, Paulson V, Roy S, Rushton C, Segal J, Senaratne T, Siddon A, Starostik P, Van Ziffle J, Wu D, Xian R, Yohe S, Kim A. Current clinical practices and challenges in molecular testing: a GOAL Consortium Hematopathology Working Group report. Blood Advances 2023, 7: 4599-4607. PMID: 37236162, PMCID: PMC10425685, DOI: 10.1182/bloodadvances.2023010149.Peer-Reviewed Original ResearchConceptsMolecular testingAcute casesHematologic malignanciesRapid turnaround timeTertiary care laboratoryAcute myeloid leukemiaCurrent clinical practiceMyeloid leukemiaTurnaround timeLymphoid processesClinical practicePatient careNGS panelCalendar daysClinical expectationsWorking Group ReportMost survey respondentsMalignancyCareReimbursementCase reimbursementSurvey respondentsGroup ReportTesting practicesDaysHelicobacter pylori–negative mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach: A clinicopathologic analysis
Gu S, Siddon A, Huntington S, Jain D. Helicobacter pylori–negative mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach: A clinicopathologic analysis. American Journal Of Clinical Pathology 2023, 160: 612-619. PMID: 37556379, PMCID: PMC10691190, DOI: 10.1093/ajcp/aqad088.Peer-Reviewed Original ResearchConceptsHP-positive patientsLymphoid tissue lymphomaChronic gastritisMALT lymphomaHP-negative casesTissue lymphomaHelicobacter pylori-negative mucosaPrimary gastric MALT lymphomaB-cell gene rearrangementsAvailable pathology reportsHP-negative patientsGastric MALT lymphomaHP-negative groupHelicobacter pylori infectionReview of slidesMALT lymphoma casesAdditional laboratory testingHP eradicationDisease recurrenceOptimal management strategyClinicopathologic analysisClinicopathologic featuresHistologic gastritisHP-positive casesInitial diagnosisMolecular Techniques and Gene Mutations in Myelodysplastic Syndromes
Mendoza H, Siddon A. Molecular Techniques and Gene Mutations in Myelodysplastic Syndromes. Clinics In Laboratory Medicine 2023, 43: 549-563. PMID: 37865502, DOI: 10.1016/j.cll.2023.06.002.Peer-Reviewed Original ResearchMolecular findings in myeloid neoplasms
Tran T, Siddon A. Molecular findings in myeloid neoplasms. International Journal Of Laboratory Hematology 2023, 45: 442-448. PMID: 37345257, DOI: 10.1111/ijlh.14118.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMyeloid neoplasmsNext-generation sequencingMyeloproliferative neoplasmsInternational diagnostic guidelinesSomatic gene mutationsHematologic cancersMyeloid leukemiaDiagnostic guidelinesClinical relevanceMyeloid disordersPatient careNeoplasmsCytogenetic findingsMolecular findingsGene mutationsNew molecular technologiesMolecular technologiesMutationsLeukemiaCancerPrognosticationCliniciansFindingsModifier mutationsOptimizing Donor Chimerism Threshold for Next-Generation Sequencing Monitoring of Measurable Residual Disease Post-Allogeneic Stem Cell Transplantation for Myeloid Neoplasms
Puzo C, Tormey C, Rinder H, Siddon A. Optimizing Donor Chimerism Threshold for Next-Generation Sequencing Monitoring of Measurable Residual Disease Post-Allogeneic Stem Cell Transplantation for Myeloid Neoplasms. Transplantation And Cellular Therapy 2023, 29: 459.e1-459.e4. PMID: 37062510, DOI: 10.1016/j.jtct.2023.04.005.Peer-Reviewed Original ResearchConceptsAllogeneic stem cell transplantationStem cell transplantationDonor chimerismCell transplantationNGS testingPost allogeneic stem cell transplantationMeasurable residual diseaseNext-generation sequencingAcute myeloid leukemiaConditioning regimenRelated donorsMyelodysplastic syndromeResidual diseaseValidation cohortMyeloid leukemiaMyeloid neoplasmsNGS panelLogistic regressionPatientsChimerismSignificant predictorsCharacteristic curveTransplantationRegimenConservative thresholdMyeloid sarcoma with NPM1 mutation may be clinically and genetically distinct from AML with NPM1 mutation: a study from the Bone Marrow Pathology Group
de M, Wu L, Hirt C, Pihan G, Patel S, Tam W, Bueso-Ramos C, Kanagal-Shamanna R, Raess P, Siddon A, Narayanan D, Morgan E, Pinkus G, Mason E, Hsi E, Rogers H, Toth L, Foucar K, Hurwitz S, Bagg A, Rets A, George T, Orazi A, Arber D, Hasserjian R, Weinberg O, Group F. Myeloid sarcoma with NPM1 mutation may be clinically and genetically distinct from AML with NPM1 mutation: a study from the Bone Marrow Pathology Group. Leukemia & Lymphoma 2023, 64: 972-980. PMID: 36960680, DOI: 10.1080/10428194.2023.2185091.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMyeloid sarcomaOverall survivalNPM1 mutationsDe novo acute myeloid leukemiaBone Marrow Pathology GroupMulti-institutional cohort studyNovo acute myeloid leukemiaRetrospective multi-institutional cohort studyShorter overall survivalPoor overall survivalFrequent cytogenetic abnormalityCohort studyMyeloid leukemiaPathology groupCytogenetic abnormalitiesComplex karyotypeUnique genetic landscapeMutations of genesGene mutationsSarcomaGenetic landscapeHigher average numberMutationsLeukemiaQuantitative Risk for Single-Positive Lupus Anticoagulant Results With Different Anticoagulants
Khan W, Tormey C, Rinder H, Siddon A. Quantitative Risk for Single-Positive Lupus Anticoagulant Results With Different Anticoagulants. American Journal Of Clinical Pathology 2023, 159: 417-419. PMID: 36940149, DOI: 10.1093/ajcp/aqac183.Peer-Reviewed Original ResearchAn interactive e-learning module on peripheral blood smear analysis is an effective option for teaching pathology trainees.
Moore M, Courville E, Prakash S, Brown L, Beck R, Qualtieri J, Siddon A, Wake L. An interactive e-learning module on peripheral blood smear analysis is an effective option for teaching pathology trainees. American Journal Of Clinical Pathology 2023, 160: 150-156. PMID: 36905942, DOI: 10.1093/ajcp/aqad014.Peer-Reviewed Original ResearchConceptsGraduate Medical Education (ACGME) residency programsSame educational contentMultiple-choice testNarrative-based methodsE-learningEducational contentAccreditation CouncilInteractive groupsPostintervention testsResidency programsPathology traineesTraineesSame questionsExperienceSimilar exerciseMost participantsCurriculumEducationParticipantsBlood smear analysisPretest“Double‐hit” ineffective erythropoiesis—concurrent β‐thalassemia with α‐gene triplication and myelodysplastic syndrome with SF3B1 mutation
Chen P, Gorshein E, Tormey C, Siddon A, Perincheri S. “Double‐hit” ineffective erythropoiesis—concurrent β‐thalassemia with α‐gene triplication and myelodysplastic syndrome with SF3B1 mutation. American Journal Of Hematology 2023, 98: 984-988. PMID: 36688500, DOI: 10.1002/ajh.26856.Peer-Reviewed Educational MaterialsRecent Advances in the Classification of Gynecological Tract Tumors: Updates From the 5th Edition of the World Health Organization "Blue Book".
Parkash V, Aisagbonhi O, Riddle N, Siddon A, Panse G, Fadare O. Recent Advances in the Classification of Gynecological Tract Tumors: Updates From the 5th Edition of the World Health Organization "Blue Book". Archives Of Pathology & Laboratory Medicine 2023, 147: 1204-1216. PMID: 36596270, DOI: 10.5858/arpa.2022-0166-ra.Peer-Reviewed Original ResearchConceptsWorld Health Organization classificationOrganization classificationWorld Health OrganizationTract tumorsGynecological tumorsFemale genital tract tumorsHealth OrganizationGenital tract tumorsHuman papillomavirus associationFemale genital tumorsLower genital tractFallopian tube tumorsRoutine clinical practiceGenetic tumor syndromesSite of originGenital tumorsGenital tractDiagnostic criteriaGlandular lesionsClinical practiceTumor syndromeTumorsComprehensive updateSyndromeLesions
2022
Recognizing the microgranular variant of acute promyelocytic leukemia when considering leukapheresis
Gisriel S, Chen P, Tormey C, Siddon A. Recognizing the microgranular variant of acute promyelocytic leukemia when considering leukapheresis. Transfusion 2022, 63: 277-278. PMID: 36426743, DOI: 10.1111/trf.17195.Peer-Reviewed Original ResearchConcurrent IRF4 Rearrangements in a Patient with B Cell and T Cell Disorders
Bernhisel A, Siddon A, Katz S. Concurrent IRF4 Rearrangements in a Patient with B Cell and T Cell Disorders. American Journal Of Clinical Pathology 2022, 158: s105-s105. DOI: 10.1093/ajcp/aqac126.221.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaIRF4 rearrangementB cellsCD30-positive T-cell lymphoproliferative disordersT-cell lymphoproliferative disorderLarge B-cell lymphomaPast medical historyT-cell lesionsCell lymphoproliferative disordersT-cell disordersB-cell lymphomaT-cell neoplasmsT cell linesIRF4 gene rearrangementT cell developmentLymphomatoid papulosisHodgkin's diseaseHematopoietic progenitor cellsLymphoproliferative disordersIntroduction/ObjectiveCase reportMedical historyCommon lymphoid progenitorsCell lesionsCell neoplasmsNPM1 mutations may be associated with adverse outcome in the setting of myeloid neoplasms with complex karyotype
Ramia de Cap M, Wu L, Pihan G, Narayanan D, Morgan E, Pinkus G, Cin P, Hurwitz S, Bagg A, Patel S, Tam W, Ouseph M, Gagan J, Madanat Y, Siddon A, Raess P, Rogers H, Bueso-Ramos C, Kanagal-Shamanna R, Kurzer J, Arber D, Hasserjian R, Weinberg O. NPM1 mutations may be associated with adverse outcome in the setting of myeloid neoplasms with complex karyotype. Leukemia Research 2022, 123: 106965. PMID: 36332291, DOI: 10.1016/j.leukres.2022.106965.Peer-Reviewed Original ResearchAutoimmune hemolytic anemias and paroxysmal nocturnal hemoglobinuria
Tormey C, Siddon A. Autoimmune hemolytic anemias and paroxysmal nocturnal hemoglobinuria. 2022, 346-363. DOI: 10.1002/9781119719809.ch31.ChaptersParoxysmal nocturnal hemoglobinuriaAutoimmune hemolytic anemiaHemolytic anemiaNocturnal hemoglobinuriaMainstay of therapyChoice of therapyDegree of anemiaBone marrow dysfunctionTypes of symptomsBlood transfusionCold autoantibodiesMarrow dysfunctionRBC destructionPNH patientsPrimary disorderSevere hemolysisRare typeAnemiaAutoantibodiesSingle disorderMedical issuesUnique entityPatientsTherapyHemoglobinuriaAutomated analysers underestimate atypical basophil count in myeloid neoplasms
Shah HP, Tormey CA, Siddon AJ. Automated analysers underestimate atypical basophil count in myeloid neoplasms. International Journal Of Laboratory Hematology 2022, 44: 831-836. PMID: 35609868, DOI: 10.1111/ijlh.13882.Peer-Reviewed Original ResearchConceptsMyeloid neoplasmsBasophil percentageBasophil countsMyeloproliferative neoplasmsManual differentialMyeloid disordersFlow cytometryTertiary care centerChronic myeloid leukemiaMyeloid neoplasms patientsControl patientsMyelodysplastic diseasesMean ageNeoplasm patientsControl subjectsCare centerMyeloid leukemiaPatientsNeoplasmsAtypical appearanceScatter propertiesMyeloid diseasesBasophilsDisorder diagnosisCytometry